MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-13-2026
Annovis Bio Operating Income 2011-2026 | ANVS
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Annovis Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -29.7 M | -26.7 M | -45 M | -25.5 M | -14.5 M | -6.64 M | -1.61 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.61 M | -45 M | -21.4 M |
Quarterly Operating Income Annovis Bio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.43 M | -6.27 M | -6.28 M | - | -4.39 M | -7.76 M | -7.81 M | - | -14.9 M | -9.76 M | -9.97 M | - | -6.48 M | -5.97 M | -5.25 M | - | -2.85 M | -2.53 M | -3.23 M | - | -1.6 M | -2.54 M | -583 K | - | -242 K | -306 K | -187 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -187 K | -14.9 M | -5.06 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Autolus Therapeutics plc
AUTL
|
-271 M | $ 1.35 | -2.91 % | $ 359 M |  Britain |
 |
Coherus BioSciences
CHRS
|
-181 M | $ 1.61 | -3.59 % | $ 189 M |  USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Catalyst Pharmaceuticals
CPRX
|
258 M | $ 24.88 | -0.4 % | $ 3.04 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-85.3 M | $ 10.02 | -1.16 % | $ 133 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Cardiff Oncology
CRDF
|
-49 M | $ 1.57 | -0.63 % | $ 105 M | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-147 M | $ 20.25 | -0.54 % | $ 2.83 B | France |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.55 | -4.14 % | $ 16 M | USA |
 |
Dyadic International
DYAI
|
-7.19 M | $ 0.87 | - | $ 31.5 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Entera Bio Ltd.
ENTX
|
-11.1 M | $ 1.17 | -2.1 % | $ 64 M |  Israel |
 |
Equillium
EQ
|
-23.6 M | $ 2.0 | -0.5 % | $ 115 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Evogene Ltd.
EVGN
|
-31 M | $ 0.8 | 2.49 % | $ 27.9 M | Israel |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Fate Therapeutics
FATE
|
-148 M | $ 1.15 | -3.78 % | $ 137 M | USA |
 |
Forte Biosciences
FBRX
|
-70.7 M | $ 26.15 | -1.1 % | $ 339 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-6.28 M | $ 6.2 | -3.43 % | $ 177 M | USA |
|
Foghorn Therapeutics
FHTX
|
-86.4 M | $ 4.75 | -2.59 % | $ 299 M | USA |
 |
Amicus Therapeutics
FOLD
|
32.8 M | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
15.3 B | $ 88.37 | -3.19 % | $ 27.2 B | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
-17.3 M | $ 3.52 | -0.56 % | $ 237 B | Britain |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Fulcrum Therapeutics
FULC
|
-84.8 M | $ 7.45 | -4.85 % | $ 472 K | USA |
 |
Galectin Therapeutics
GALT
|
-20.1 M | $ 2.38 | -7.03 % | $ 152 M | USA |
 |
Allakos
ALLK
|
-196 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
502 M | $ 315.4 | -4.52 % | $ 41.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
Gilead Sciences
GILD
|
10 B | $ 138.37 | -1.26 % | $ 172 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-30.2 M | $ 0.54 | 4.26 % | $ 503 K | Israel |
 |
Aileron Therapeutics
ALRN
|
-50.6 M | - | 10.36 % | $ 9.8 M | USA |
 |
Genmab A/S
GMAB
|
2.64 B | $ 27.13 | -2.25 % | $ 17 B |  Danmark |
 |
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | USA |